(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of -0.27% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Collegium Pharmaceutical's revenue in 2024 is $566,767,000.On average, 5 Wall Street analysts forecast COLL's revenue for 2024 to be $18,617,302,926, with the lowest COLL revenue forecast at $18,520,720,326, and the highest COLL revenue forecast at $18,743,480,327. On average, 5 Wall Street analysts forecast COLL's revenue for 2025 to be $19,025,557,769, with the lowest COLL revenue forecast at $18,546,288,188, and the highest COLL revenue forecast at $19,361,263,802.
In 2026, COLL is forecast to generate $17,477,104,102 in revenue, with the lowest revenue forecast at $16,504,055,179 and the highest revenue forecast at $18,216,143,165.